BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21907239)

  • 1. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
    Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
    J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.
    Erali M; Page S; Reimer LG; Hillyard DR
    J Clin Microbiol; 2001 Jun; 39(6):2157-65. PubMed ID: 11376051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter.
    Gale HB; Kan VL; Shinol RC
    Clin Vaccine Immunol; 2006 Feb; 13(2):235-8. PubMed ID: 16467331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized protocol for detection of HIV-1 drug mutations in patients with low viral load.
    Stelzl E; Troppan KT; Winkler M; Korn K; Kessler HH
    J Virol Methods; 2010 Sep; 168(1-2):152-4. PubMed ID: 20471425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
    Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
    AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing.
    De Wolf H; Van Marck H; Mostmans W; Thys K; Vandenbroucke I; Van Eygen V; Pattery T; Verhasselt P; Aerssens J
    J Virol Methods; 2011 Jul; 175(1):129-32. PubMed ID: 21549149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
    Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical utility of drug resistance testing].
    Sugiura W
    Nihon Rinsho; 2002 Apr; 60(4):703-10. PubMed ID: 11968776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
    Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
    J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory.
    Ram D; Leshkowitz D; Gonzalez D; Forer R; Levy I; Chowers M; Lorber M; Hindiyeh M; Mendelson E; Mor O
    J Virol Methods; 2015 Feb; 212():12-6. PubMed ID: 25445792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
    Bellecave P; Recordon-Pinson P; Fleury H
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naïve HIV-1 patients with acute and chronic infection.
    Re MC; Monari P; Bon I; Borderi M; Chiodo F;
    Int J Antimicrob Agents; 2004 Feb; 23(2):164-8. PubMed ID: 15013042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
    de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
    J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.